Preeclampsia and soluble fms-like tyrosine kinase 1

Journal of Clinical Endocrinology and Metabolism

Volumn 94, Issue 7, 2009, Pages 2252-2254

  Roberts, James M ^a,b   Rajakumar, Augustine ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANTIOXIDANT; FMS LIKE TYROSINE KINASE 1; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; VASCULOTROPIN;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CYTOTROPHOBLAST; EDITORIAL; EXON; HUMAN; HYPERTENSION; MULTIPLE ORGAN FAILURE; OXIDATIVE STRESS; PATHOGENESIS; PERINATAL MORBIDITY; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; VASCULAR ENDOTHELIUM;

EID: 67650257706     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-0945     Document Type: Editorial

References (20)

1. Starzyk KA, Pijnenborg R, Salafia CM 1999 Decidual and vascular pathophysiology in pregnancy compromise. Semin Reprod Endocrinol 17:63-72
2. Roberts JM, Gammill HS 2005 Preeclampsia: recent insights. Hypertension 46:1243-1249
3. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA 2003 Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649-658
4. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L 2006 VEGF receptor signalling: in control of vascular function. Nat Rev Mol Cell Biol 7:359-371
5. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA 2004 Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350:672-683
6. Huckle WR, Roche RI 2004 Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. J Cell Biochem 93:120-132
7. Heydarian M, McCaffrey T, Florea L, Yang Z, Ross MM, Zhou W, Maynard SE 2009 Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 30:250-255
8. Rajakumar A, Powers RW, Hubel CA, Shibata E, von Versen-Höynck F, Plymire D, Jeyabalan A 2009 Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta 30:25-34
9. Thomas CP, Andrews JC, Raikwar NS, Kelley EA, Herse F, Dechend R, Golos TG, Liu KZ 2009 A recently evolved novel trophoblast-enriched sFlt1 variant is upregulated in hypoxia and in preeclampsia. J Clin Endocrinol Metab 94:2524-2530
10. Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60-65
11. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S 2005 Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 39:733-742
12. Gammill HS, Lin C, Hubel CA 2007 Endothelial progenitor cells and preeclampsia. Front Biosci 12:2383-2394
13. Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, During MJ 2004 VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 36:827-835
14. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ, Moore MW 1996 Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439-442
15. Miquerol L, Langille BL, Nagy A 2000 Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. Development 127:3941-3946
16. Sela S, Itin A, Natanson-Yaron S, Greenfield C, Goldman-Wohl D, Yagel S, Keshet E 2008 A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102:1566-1574
17. Mazzone M, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, Jonckx B, Tian YM, Lanahan AA, Pollard P, Ruiz de Almodovar C, De Smet F, Vinckier S, Aragonés J, Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani MG, Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P 2009 Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136:839-851
18. Makris A, Thornton C, Thompson J, Thomson S, Martin R, Ogle R, Waugh R, McKenzie P, Kirwan P, Hennessy A 2007 Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 71:977-984
19. Rumbold A, Duley L, Crowther CA, Haslam RR 2008 Antioxidants for preventing pre-eclampsia. Cochrane Database Syst Rev CD00427
20. Roberts JM, Hubel CA 2009 The two stage model of preeclampsia: variations on the theme. Placenta 30:S32-S37